Bavarian Nordic has received funding from the US National Institutes of Health to develop a vaccine for filoviruses such as Ebola and Marburg.

The company is investigating the use of core vaccine technology MVA-BN as a combined vaccine.

The funding will support an animal efficacy study, which will be conducted in non-human primates.

The results of this study, expected in 2011, will be used to determine the future of the project.

Filoviruses can cause severe hemorrhagic fever in humans and non-human primates, and the Marburg and Ebola viruses are considered to be potential biological weapons.